Morten Marott
Nessuna posizione attualmente
Profilo
Morten Marott worked as an Associate at Citigroup Global Markets, Inc. and as the Chief Financial Officer at Veloxis Pharmaceuticals A in 2018.
He completed his undergraduate degree at Copenhagen Business School, his graduate degree at the University of Copenhagen, and his MBA at The Wharton School of the University of Pennsylvania.
Precedenti posizioni note di Morten Marott
Società | Posizione | Fine |
---|---|---|
VELOXIS PHARMACEUTICALS A/S | Direttore Finanziario/CFO | 24/09/2018 |
Citigroup Global Markets, Inc. (Broker)
Citigroup Global Markets, Inc. (Broker) Investment Banks/BrokersFinance Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis. | Analyst-Equity | - |
Formazione di Morten Marott
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Copenhagen Business School | Undergraduate Degree |
University of Copenhagen | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Citigroup Global Markets, Inc. (Broker)
Citigroup Global Markets, Inc. (Broker) Investment Banks/BrokersFinance Citigroup Global Markets, Inc. (Broker) (CGMI-Broker) is the broker/dealer division of Citigroup Global Markets, Inc., an investment bank headquartered in New York City with additional offices across the US. The firm was founded in 2004 and is a subsidiary of Citigroup Financial Products, Inc., ultimately held by Citigroup, Inc. (NYSE: C). CGMI-Broker covers all market capitalizations of the major global indices and provides macro and quantitative analysis of global markets and sector trends. Their core focus of the group is to help investing clients make informed decisions by providing value-added, independent, insightful analysis. | Finance |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Morten Marott